Department of Clinical and Experimental Medicine, Division of Pediatrics and Diabetes Research Center, Faculty of Health Sciences, Linköping University, SE 581 85 Linköping, Sweden.
Expert Opin Biol Ther. 2010 May;10(5):787-99. doi: 10.1517/14712591003742920.
Type 1 diabetes is a common and very serious disease. There has been very active research going on for a long time aiming at preservation of the residual insulin secretion by some kind of intervention to stop the destructive autoimmune process. This review covers a new type of immune intervention using auto-antigen treatment.
Immune interventions in type 1 diabetes have been tried during the last 30 years, this review mentions some of them, but the main topic is the use of the auto-antigen glutamic acid decarboxylase (GAD) to create tolerance to stop the autoimmune process. The clinical trials have been performed during the last 15 years and are all covered.
This review will give the reader a picture of the research behind treatment with GAD as an immune intervention in type 1 diabetes.
The key finding so far is that treatment with Diamyd has not only been shown to preserve residual beta cell function in type 1 diabetes, but this treatment may be the proof in humans of a new concept of treating and perhaps even preventing autoimmune diseases.
1 型糖尿病是一种常见的和非常严重的疾病。已经有非常活跃的研究进行了很长一段时间旨在保护残留的胰岛素分泌通过某种干预措施来阻止破坏性的自身免疫过程。这篇综述涵盖了一种新的免疫干预类型，使用自身抗原治疗。
在过去的 30 年中，已经尝试了 1 型糖尿病的免疫干预，这篇综述提到了其中的一些，但主要的主题是使用谷氨酸脱羧酶（GAD）自身抗原来产生耐受性，以阻止自身免疫过程。临床试验已经在过去的 15 年中进行，并全部涵盖。
这篇综述将使读者了解到用 GAD 作为 1 型糖尿病免疫干预治疗的研究背景。
到目前为止的主要发现是，用 Diamyd 治疗不仅显示出可以保留 1 型糖尿病患者的残余β细胞功能，而且这种治疗可能是人类治疗甚至预防自身免疫性疾病的新概念的证据。
